Page last updated: 2024-10-24

protein lipidation

Definition

Target type: biologicalprocess

The covalent attachment of lipid groups to an amino acid in a protein. [GOC:jl]

Protein lipidation is a crucial post-translational modification process that involves the covalent attachment of lipid molecules to proteins. This modification plays a critical role in regulating various cellular processes, including protein trafficking, membrane association, signal transduction, and protein-protein interactions.

There are several types of lipidation, each with unique mechanisms and functional consequences:

**1. Myristoylation:** Involves the attachment of myristate, a 14-carbon saturated fatty acid, to the N-terminal glycine residue of a protein. This modification typically occurs co-translationally and is often involved in protein targeting to membranes and protein-protein interactions.

**2. Palmitoylation:** This reversible modification involves the attachment of palmitic acid, a 16-carbon saturated fatty acid, to cysteine residues within a protein. Palmitoylation can occur at the plasma membrane and is often involved in membrane association, protein trafficking, and signal transduction.

**3. Prenylation:** This process involves the attachment of isoprenoid lipids, such as farnesyl or geranylgeranyl, to cysteine residues near the C-terminus of a protein. Prenylation is often involved in protein-protein interactions, membrane association, and signal transduction.

**4. Glycosylphosphatidylinositol (GPI) anchoring:** This modification involves the attachment of a GPI anchor, a complex glycolipid, to the C-terminus of a protein. GPI anchoring is typically involved in targeting proteins to the outer leaflet of the plasma membrane, where they can interact with other membrane-associated proteins.

**5. Fatty acylation:** This term encompasses a range of lipid modifications, including myristoylation and palmitoylation, that involve the attachment of fatty acids to proteins. Fatty acylation is often involved in protein membrane association and protein-protein interactions.

The specific type of lipidation and the location of lipid attachment within a protein determine the functional consequences of the modification. For instance, myristoylation and palmitoylation can target proteins to specific membrane compartments, while prenylation can modulate protein-protein interactions.

Overall, protein lipidation is a highly regulated process that plays a vital role in maintaining cellular function and homeostasis. Understanding the molecular mechanisms and functional consequences of lipidation is crucial for gaining insights into various cellular processes and for developing therapeutic strategies targeting these modifications.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Protein-serine O-palmitoleoyltransferase porcupineA protein-serine O-palmitoleoyltransferase porcupine that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9H237]Homo sapiens (human)
Phosphatidylinositol 3-kinase catalytic subunit type 3A phosphatidylinositol 3-kinase catalytic subunit type 3 that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)
Ceramide glucosyltransferaseA ceramide glucosyltransferase that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q16739]Homo sapiens (human)
Ubiquitin-like modifier-activating enzyme ATG7A ubiquitin-like modifier-activating enzyme ATG7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95352]Homo sapiens (human)

Compounds (33)

CompoundDefinitionClassesRoles
1-deoxynojirimycin1-deoxy-nojirimycin: structure in first source

duvoglustat : An optically active form of 2-(hydroxymethyl)piperidine-3,4,5-triol having 2R,3R,4R,5S-configuration.
2-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid
anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite
miglustatmiglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.

miglustat: a glucosylceramide synthase inhibitor
piperidines;
tertiary amino compound
anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
migalastatmigalastat: a potent inhibitor of glycolipid biosynthesispiperidines
miglitolpiperidines
N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamideorganic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
ML162ML162 : A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells.monochlorobenzenes;
monomethoxybenzene;
organochlorine compound;
secondary carboxamide;
tertiary carboxamide;
thiophenes
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer
n-(5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin
PI3-Kinase alpha Inhibitor 2organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
l-altro-1-deoxynojirimycinL-altro-1-deoxynojirimycin: structure in first source
idelalisibidelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.

idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source
aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound
antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
zstk474ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
dactolisibdactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.

dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR
imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
ku 60019
buparlisibNVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first sourceaminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound
antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
pevonedistatpevonedistat : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine which is substituted by a (1S)-2,3-dihydro-1H-inden-1-ylnitrilo group at position 4 and by a (1S,3S,4S)-3-hydroxy-4-[(sulfamoyloxy)methyl]cyclopentyl group at position 7. It is a potent and selective NEDD8-activating enzyme inhibitor with an IC50 of 4.7 nM, and currently under clinical investigation for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes.

pevonedistat: a potent and selective inhibitor of NAE (NEDD8-activating enzyme)
cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate
antineoplastic agent;
apoptosis inducer
gdc 0941pictrelisib : A sulfonamide composed of indazole, morpholine, and methylsulfonyl-substituted piperazine rings bound to a thienopyrimidine ring.indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
gdc 0980
azd2014vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source
pki 587gedatolisib: inhibits both phosphatidylinositol 3-kinase and mTOR; structure in first source
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-aminesapanisertib: an mTOR inhibitorbenzoxazole
lgk974LGK974 : A carboxamide, the structure of which is that of acetamide substituted on carbon by a 2',3-dimethyl-2,4'-bipyridin-5-yl group and on nitrogen by a 5-(pyrazin-2-yl)pyridin-2-yl group. It is a highly potent, selective and orally bioavailable Porcupine inhibitor (a Wnt signalling inhibitor).

LGK974: a potent and specific small-molecule inhibitor of Porcupine (PORCN) acyltransferase
bipyridines;
pyrazines;
pyridines;
secondary carboxamide
Wnt signalling inhibitor
ch 5132799CH 5132799: structure in first source
torin 1torin 1 : A member of the class of pyridoquinolines that is 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2-one bearing an additional 4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl substituent at position 1. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines
antineoplastic agent;
mTOR inhibitor
gdc-0032
spautin-1
torin 2torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline
antineoplastic agent;
mTOR inhibitor
cudc-907
sar245408
byl719proline derivative
amg 511AMG 511: structure in first source
wnt-c592-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl)acetamide: a PORCN acyltransferase inhibitor; structure in first source
cc-223
sar405SAR405: a Vps34 inhibitor with antineoplastic activity; structure in first source